DYNAMIC-TZ: Dynamic CDSA to Manage Sick Children in Tanzania

Sponsor
Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland (Other)
Overall Status
Recruiting
CT.gov ID
NCT05144763
Collaborator
Swiss Tropical & Public Health Institute (Other), Ecole Polytechnique Fédérale de Lausanne (Other), Ifakara Health Institute (Other), National Institute for Medical Research, Tanzania (Other), University of Geneva, Switzerland (Other)
40,000
40
2
28
1000
35.8

Study Details

Study Description

Brief Summary

This study aims to reduce morbidity and mortality among children and mitigate antimicrobial resistance using a novel clinical decision support algorithm, enhanced with point-of-care technologies to help health workers in primary health care settings in Tanzania. Furthermore, the tool provides opportunities to improve supervision and mentorship of health workers and enhance disease surveillance and outbreak detection.

Condition or Disease Intervention/Treatment Phase
  • Device: ePOCT+
N/A

Detailed Description

Children are a well-recognized vulnerable population that still suffers from a high rate of acute infectious diseases and preventable deaths. This is especially true in fragile health systems of Sub-Saharan Africa, where under-five mortality is 10 times higher than in high-income countries. The management of sick children at the primary care level in these environments remains of insufficient quality as front-line clinicians lack appropriate diagnostics, supervision to improve their skills, and decision support tools. Clinically validated point-of-care (POC) diagnostic tests are often not available, and practice guidelines are quickly outdated by new evidence and changing epidemiology. When an epidemic arises, these static, generic guidelines can even become deleterious if the event is not detected on time and integrated into the recommendations.

In the absence of reliable guidance, health care workers (HCWs) tend to over-prescribe antibiotics (Hopkins et al. 2017, Fink et al. 2019). Approximately 9 out of 10 children at the primary care level in Tanzania receive an antibiotic, while only 1 in 10 needs one (D'Acremont et al. 2014). Inappropriate antibiotic use disrupts the gut flora, favoring the proliferation of pathogens and weakening a child's immune response (Benoun et al. 2016). It is also a major driver of antibiotic resistance, which is estimated to be responsible for up to 10 million deaths per year by 2050 (Holmes et al. 2016, Fink et al. 2019). Equally important to antibiotic overuse, is its underuse. Missing a child in need of antibiotic treatment or providing a child with an inappropriate type or dosage of antibiotic puts them at risk of preventable morbidity and death. The same occurs with antimalarials that are not always prescribed to the children in need: those with a positive malaria test result.

Misdiagnoses have consequences that reach beyond the patient. They increase re-attendance rates, further congesting primary health facilities and accruing economic losses not only for families but for the entire health system. Systematic errors in patient-level data accumulate, and as they are aggregated to measure population-level indicators, they have the potential to bias the statistics used to prioritize health interventions and, importantly, identify epidemics.

The WHO has identified digital health interventions and predictive tools in primary care as key accelerators in achieving the 2030 Sustainable Development Goal 3 of ensuring good health and well-being for all. New simple and cheap technologies, such as mobile devices, coupled with the advances in computing and data science, could help mitigate several of the aforementioned challenges. The proposed digital intervention is a third-generation clinical decision support algorithm (CDSA) intended to help HCWs at the primary care level manage children with acute illnesses. The first two versions of the algorithm have undergone rigorous evaluations in controlled research conditions as summarized below:

The first-generation algorithm called ALMANACH was tested in Tanzania in 2010-2011, achieving improved clinical cure (from 92% to 97%) and a decrease in antibiotic prescription (from 84% to 15%) as compared to routine care (Shao et al. 2015A). ALMANACH also led to more consistent clinical assessments without taking more time than a conventional consultation and was perceived by clinicians as "a powerful and useful" tool (Shao et al. 2015B).

The second-generation algorithm called ePOCT was trialed in Tanzania in 2014-2016. In addition to symptoms and signs, it made use of several POC tests to help detect children with severe infections requiring hospital-based treatment (oximetry and hemoglobin level) and/or children with serious bacterial infection (CRP). The use of ePOCT resulted in higher clinical cure (98%) as compared to ALMANACH (96%) and routine care (95%). The algorithm also further reduced antibiotic prescription to 11%, as compared to 30% with the use of ALMANACH and 95% in routine care (Keitel et al. 2017).

Electronic algorithms can thus be successfully implemented to improve clinical guidance and provide feedback to clinicians, as well as allow near-real-time analyses of data for M&E of health interventions, disease surveillance and outbreak detection. The goal of this study is to improve clinical diagnosis, decrease morbidity and mortality of children, and mitigate antimicrobial resistance using novel dynamic POC technologies that help front-line HCWs manage sick patients, enhanced by smart disease surveillance and outbreak detection mechanisms.

More specifically, this study seeks to:

Objective 1: Improve the integrated management of children with an acute illness through the provision of an electronic CDSA (ePOCT+) to clinicians working at primary care level;

Objective 2: Improve the accuracy of the clinical algorithm and adapt it to spatiotemporal variations in epidemiology and resources, based on the data generated through the ePOCT+ tool, analyzed using machine learning and checked by clinical experts;

Objective 3: Enhance the district (and national) disease surveillance and outbreak detection capability using the clinical data generated by the ePOCT+ tool complemented by targeted microbiological investigations and machine learning pattern detection;

Objective 4: Enhance the district (and national) health management information system for monitoring and evaluation and conducting supportive supervision and mentorship in health facilities using the clinical data generated by the ePOCT+ tool enhanced by additional data analysis and visualization dashboards;

Objective 5: Create a framework for the development and implementation of dynamic CDSA and disease surveillance tools, for large-scale, sustainable, and clinically responsible use of machine learning and data science.

The primary intervention study will be conducted in two phases.

Phase 1: pragmatic, open-label cluster randomized controlled study in 40 health facilities. The intervention consists of ePOCT+ clinical decision support algorithm (CDSA) displayed on tablets (medAL-reader), point-of-care tests and devices that are not part of routine care (pulse oximeter, CRP rapid test, additional hemoglobin cuvettes), complementary training on the tool, regular monitoring and mentorship/supervision visits by the study team and/or the Council Health Management Team (CHMT). Mentorship and supervision will be enabled by a complementary dashboard (medAL-monitor), used to visualize and monitor study-related indicators. Due to the pragmatic nature of the study, the design is adaptive, in that changes in the implementation throughout Phase 1 may be made based on monitoring data and feedback from the health facilities. These implementation changes (excluding significant adaptations to algorithm content) will be thoroughly documented and accounted for in longitudinal analyses.

Phase 2: scale-up of the intervention to more health facilities and transformation into a dynamic algorithm The ePOCT+ tool will be extended to the health facilities serving as controls in Phase 1, as well as to additional neighboring facilities of our target area, to reach a total of up to 100 facilities. In Phase 2, an adaptive study design will be used to measure the same outcome indicators as in Phase 1. The medical content of the algorithm will not be fixed anymore, but rather modifiable. Each potential modification will first be evaluated by the Tanzanian clinical expert group for its clinical coherence, safety and potential benefit and then applied to the retrospective data. If these analyses confirm both a clinically relevant positive impact and estimate that there will be sufficient future cases during the study period to detect this improvement, the change in the algorithm will be tested in a randomized sub-study using the same study design as in Phase 1, except that randomization will take place at patient level rather than health facility level. If the positive impact is confirmed in the sub-study, the modification will be implemented in all relevant locations/patient sub-groups.

Additional cross-sectional mixed-methods operational research studies will take place throughout the intervention period to study the implementation context, facilitators and barriers to the scale-up of this intervention and its integration into the primary health system of Tanzania.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40000 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The study involves two arms: intervention and control. Health facilities will serve as clusters, with half of the facilities (20) receiving the intervention and the other half serving as controls (20). Health facilities will be randomized to their respective study arm. A parallel design (all health facilities start at the same time) will be used. At the end of the cluster randomized controlled study, the control facilities will also receive the intervention, along with additional facilities for up to 100.The study involves two arms: intervention and control. Health facilities will serve as clusters, with half of the facilities (20) receiving the intervention and the other half serving as controls (20). Health facilities will be randomized to their respective study arm. A parallel design (all health facilities start at the same time) will be used. At the end of the cluster randomized controlled study, the control facilities will also receive the intervention, along with additional facilities for up to 100.
Masking:
None (Open Label)
Masking Description:
Masking is not possible
Primary Purpose:
Diagnostic
Official Title:
Dynamic Clinical Decision Support Algorithms to Manage Sick Children in Primary Health Care Settings in Tanzania
Actual Study Start Date :
Dec 1, 2021
Anticipated Primary Completion Date :
Sep 1, 2022
Anticipated Study Completion Date :
Mar 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: ePOCT+

Health facilities allocated to the ePOCT+ intervention arm will receive an electronic clinical decision support algorithm (ePOCT+) on a tablet that will guide them through pediatric consultations. Point-of-care tests proposed by ePOCT+ that are not part of routine care will be provided as part of the study (pulse oximeter, CRP rapid test, additional hemoglobin cuvettes, and salbutamol inhalers and spacers). Training on the use of ePOCT+ and associated clinical skills will be provided before the implementation of the study, along with mentorship visits to assist with issues related to the implementation of ePOCT+.

Device: ePOCT+
ePOCT+ is an electronic clinical decision support algorithm

No Intervention: Routine care

In health facilities allocated to the control arm, pediatric consultations will be conducted in a routine manner; however, tests/test results, diagnoses, management and treatments will be recorded in an electronic case report form on a tablet. Equivalent clinical training will be provided before the start of the study.

Outcome Measures

Primary Outcome Measures

  1. Percentage of children cured at day 7 in the intervention group (ePOCT+) as compared to the control group (routine care) [at day 7 (range 6-14) after enrollment]

    The child is defined as being cured at day 7 if the caregiver says that the child is cured or has improved since the initial consultation. Non-referred secondary hospitalizations (if caregiver says that child was hospitalized between day 0 and day 7 but the electronic clinical data does not indicate a referral for hospitalization) will however be considered as clinical failures even if the child is already cured at day 7.

  2. Percentage of children prescribed an antibiotic at initial consultation in the intervention group (ePOCT+) as compared to the control group (routine care) [by the end of the initial consultation (day 0)]

    Prescription of oral or parenteral antibiotic at initial consultation, as reported by the health care worker.

Secondary Outcome Measures

  1. Percentage of children with one or more unscheduled re-attendance visits at any health facility by day 7 [by day 7 (range 6-14) after enrollment]

    Telephone or home visit follow-up 7 days (range 6-14 days) after enrollment of the subject. The day of enrollment of the subject is considered as day 0.

  2. Percentage of children with severe clinical outcome (death or non-referred secondary hospitalization) by day 7 [by day 7 (range 6-14) after enrollment]

    Death and non-referred secondary hospitalization will be assessed by telephone or home visit follow-up 7 days (range 6-14 days) after enrollment of the subject. The day of enrollment of the subject is considered as day 0.

  3. Percentage of children referred to hospital or inpatient ward at a health centre at initial consultation [by the end of the initial consultation (day 0)]

    Documented by the health care worker at the end of the initial consultation in the eCRF (control arm) or in ePOCT+ (intervention arm) when the subject was enrolled (day 0)

  4. Percentage of febrile children tested for malaria by RDT and/or microscopy at day 0 [by the end of the initial consultation (day 0)]

    A febrile child is a child with a history of fever (measured or suspected fever in the past 48 hours) or a high temperature.

  5. Percentage of malaria positive children prescribed an antimalarial at day 0 [by the end of the initial consultation (day 0)]

    An antimalarial prescription is any oral, rectal, intramuscular or intravenous antimalarial prescribed by a HCW during the initial consultation or a re-attendance visit.

  6. Percentage of malaria negative children prescribed an antimalarial at day 0 [by the end of the initial consultation (day 0)]

    An antimalarial prescription is any oral, rectal, intramuscular or intravenous antimalarial prescribed by a HCW during the initial consultation or a re-attendance visit.

  7. Percentage of children untested for malaria prescribed an antimalarial at day 0 [by the end of the initial consultation (day 0)]

    An antimalarial prescription is any oral, rectal, intramuscular or intravenous antimalarial prescribed by a HCW during the initial consultation or a re-attendance visit.

Other Outcome Measures

  1. Change in percent of cases managed using ePOCT+ (uptake) over time [through study 1 completion, thus 6 to 9 months]

    Change in the percent of cases fully managed using ePOCT+ meaning that the medications and referral steps completed and case closed by healthcare worker. This outcome will be assessed month to month in the intervention arm only. Dated changes in implementation will be presented for context of temporal changes in outcome.

  2. Change in the percent of children with basic anthropometrics and clinical signs assessed over time [through study 1 completion, thus 6 to 9 months]

    Change in the percent of children with anthropometric measurements (weight, height, MUAC) and clinical signs (respiratory rate) assessed and documented by the healthcare worker. This outcome will be assessed month to month in the intervention arm only. Dated changes in implementation will be presented for context of temporal changes in outcome.

  3. Change in the percent of children with antibiotic prescribed over time [through study 1 completion, thus 6 to 9 months]

    Change in the percent of children with an antibiotic prescribed during initial consultation. This outcome will be compared between intervention and control arms month to month. Dated changes in implementation will be presented for context of temporal changes in outcome.

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Day to 14 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Presenting for an acute medical or surgical condition
Exclusion Criteria:
  • Presenting for scheduled consultation for a chronic disease (e.g. HIV, TB, NCD, malnutrition)

  • Presenting for routine preventive care (e.g. growth monitoring, vitamin supplementation, deworming, vaccination)

  • Caregiver unavailable, unable or unwilling to provide written informed consent (except for older children who can provide verbal assent with an adult witness during the consenting process)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Isyesye Dispensary Mbeya Mbeya CC Tanzania
2 Idiga Dispensary Mbeya Tanzania
3 Iganzo Dispensary Mbeya Tanzania
4 Igoma Dispensary Mbeya Tanzania
5 Ikukwa Health Center Mbeya Tanzania
6 Inyala Health Center Mbeya Tanzania
7 Isonso Dispensary Mbeya Tanzania
8 Itagano Dispensary Mbeya Tanzania
9 Itensa Dispensary Mbeya Tanzania
10 Ituha Dispensary Mbeya Tanzania
11 Iwowo Dispensary Mbeya Tanzania
12 Iziwa Dispensary Mbeya Tanzania
13 Izumbwe II Dispensary Mbeya Tanzania
14 Ruanda Health Center Mbeya Tanzania
15 Santilya Health Center Mbeya Tanzania
16 Shuwa Dispensary Mbeya Tanzania
17 Chita Rural Dispensary Morogoro Tanzania
18 Ebuyu Dispensary Morogoro Tanzania
19 Idete Dispensary Morogoro Tanzania
20 Ikule Dispensary Morogoro Tanzania
21 Isongo Dispensary Morogoro Tanzania
22 Ketaketa Dispensary Morogoro Tanzania
23 Kibaoni Health Center Morogoro Tanzania
24 Kichangani Dispensary Morogoro Tanzania
25 Kidatu Dispensary Morogoro Tanzania
26 Kivukoni Dispensary Morogoro Tanzania
27 Lukande Dispensary Morogoro Tanzania
28 Mbingu Dispensary Morogoro Tanzania
29 Mbuga Dispensary Morogoro Tanzania
30 Michenga Dispensary Morogoro Tanzania
31 Mkangawalo Dispensary Morogoro Tanzania
32 Mlimba Health Center Morogoro Tanzania
33 Mngeta Health Center Morogoro Tanzania
34 Msolwa A Dispensary Morogoro Tanzania
35 Msolwa Station Dispensary Morogoro Tanzania
36 Mwaya Health Center Morogoro Tanzania
37 Sagamaganga Dispensary Morogoro Tanzania
38 Sonjo Dispensary Morogoro Tanzania
39 Udagaji Dispensary Morogoro Tanzania
40 Utengule Dispensary Morogoro Tanzania

Sponsors and Collaborators

  • Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland
  • Swiss Tropical & Public Health Institute
  • Ecole Polytechnique Fédérale de Lausanne
  • Ifakara Health Institute
  • National Institute for Medical Research, Tanzania
  • University of Geneva, Switzerland

Investigators

  • Principal Investigator: Valerie D'Acremont, PhD, Centre for Primary Care and Public Health

Study Documents (Full-Text)

More Information

Additional Information:

Publications

Responsible Party:
Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland
ClinicalTrials.gov Identifier:
NCT05144763
Other Study ID Numbers:
  • 2020-02800
  • NIMR/HQ/R.8a/Vol.IX/3486
  • Project_6278
First Posted:
Dec 3, 2021
Last Update Posted:
May 9, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland

Study Results

No Results Posted as of May 9, 2022